Cenk Sumen, Director at Thermo Fisher discuss durability of anticancer therapies and its importance in relation to pricing and reimbursement and providing a cure vs disease control
Expedited approval pathways for advanced therapies and huge expectations for curative effects mean that the durability for cell therapies is still an unknown. What if we thought of liquid tumours as chronic, treatable disease like HIV, that a patient lives with over their lifetime? How would that change perceptions and attitudes towards reimbursement and patient outcomes?
Cenk Sumen, Director at Thermo Fisher shares his views on the importance of better understanding of durability, the impact it has on pricing and reimbursement and how to define the 'C' word (curative!) and the need to educate healthcare and payer stakeholders.
We asked Cenk four not-so-simple questions:
- Why is durability important and what impact does it have on pricing and reimbursement
- What can drug developers do to help manage the expectations of payers?
- What are your thoughts on the commercial viability of Kymriah and Yescarta, given their differences in durability?
- What is the definition of curative treatment and who is responsible for determining this in relation to reimbursement?